Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bostwick is focused on blood-brain-barrier delivery and says transferrin-receptor shuttles will only serve a small subset of brain targets. Because some cells have TfR and others do not, he is exploring CD98, LRP1, glycocalyx interactions, scavenger receptors, and paracellular routes through BBB relaxers for delivery.

Related Insights

Bostwick says CNS teams miscast the brain as just another organ. He lists a blood-brain barrier built as an immune fortress, motor neurons whose axons stretch from spinal cord to ankle, and neurons that express roughly 10,000 genes with heavy alternative splicing and RNA transfer between cells.

Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.

While Natural Killer (NK) cells themselves are too large to cross the blood-brain barrier, the nanoscale extracellular vesicles (EVs) they produce can. This allows Avenco to harness the therapeutic potential of NK cells for neurodegenerative diseases by delivering their active cargo directly into the brain, solving a fundamental delivery challenge.

Advanced cell therapy isn't just about replacing lost cells. Transplanted, genetically engineered cells can be programmed to produce and secrete therapeutics locally. This turns them into a delivery platform that solves the critical challenge of the blood-brain barrier for large molecules.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

Bio Arctic's "brain transporter" technology is differentiated from competitors. By carefully selecting where its antibody binds on the transferrin receptor, it avoids impacting red blood cells (reticulocytes). This preclinical finding suggests a better safety profile, a key competitive advantage that likely attracts major pharma partners.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.

Voyager's ALPL-based blood-brain barrier shuttle offers a different pharmacokinetic profile than transferrin receptor shuttles. While delivering a lower initial peak concentration (Cmax), it provides a much longer half-life. This steady, sustained exposure is optimal for therapies that require constant pathway blockage, highlighting a key strategic trade-off in delivery system design.

Arrowhead's demonstration of over 80% tau knockdown in CSF signals that transferrin-mediated delivery is expanding beyond enzymes and antibodies into siRNA conjugates. Much like GalNAc revolutionized liver targeting, transferrin technology is maturing across multiple competitors to overcome blood-brain barrier penetration challenges.

CNS therapeutic delivery is a multi-layered hierarchy rather than just crossing the blood-brain barrier. Effective delivery requires achieving adequate exposure in specific anatomical brain regions, verifying target engagement within precise cell types, and achieving proper intracellular trafficking for advanced modalities like ASOs, siRNAs, and AAVs.